Relief for AZ as Truqap hits the spot in prostate cancer
After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Newsletters and Deep Dive digital magazine
After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Jazz Pharma has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary tract cancer
9th Liquid Biopsy for Precision Oncology Summit | February 18-20, 2025 | San Diego, CA | FREE* to Attend for Biopharma
Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets
Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug
Editor's Picks
Newsletters and Deep Dive
digital magazine